Leadership Overview
Penumbra has 4 executives leading key functions including strategy, financial operations, clinical development, and international market expansion.
Focused on advancing neurovascular and peripheral vascular care, Penumbra delivers innovative medical device solutions to improve patient outcomes across global healthcare markets through rigorous engineering and clinical excellence.
Focused on advancing neurovascular and peripheral vascular care, Penumbra delivers innovative medical device solutions to improve patient outcomes across global healthcare markets through rigorous engineering and clinical excellence.
Leadership Roles at Penumbra
Adam Elsesser - Chairman & Chief Executive Officer
Adam Elsesser, the Chairman & Chief Executive Officer at Penumbra, directs the overarching corporate strategy and long-term vision for the organization. Overseeing the development of neurovascular access systems and aspiration-based thrombectomy technologies, the Chairman & Chief Executive Officer ensures alignment between engineering innovation and clinical requirements. This leadership role involves managing high-level board relations while driving the expansion of the company's product portfolio across international markets. By prioritizing research and development, Adam Elsesser maintains the competitive edge of the firm within the medical device sector. The Chairman & Chief Executive Officer fosters a culture of rapid iteration, ensuring that the company remains at the forefront of mechanical thrombectomy advancements. Through consistent focus on operational efficiency and market penetration, the executive secures the financial health and technological leadership of the enterprise, ultimately delivering value to patients and stakeholders worldwide.
Maggie Yuen - Chief Financial Officer
Maggie Yuen, the Chief Financial Officer at Penumbra, manages the fiscal health and capital allocation strategies for the organization. Overseeing global financial reporting, tax compliance, and investor relations, the Chief Financial Officer ensures the company maintains the necessary resources to support the manufacturing and marketing of complex medical devices. This leadership role involves analyzing market trends across the United States, Europe, and Asia to optimize revenue growth and cost structures. By implementing robust financial controls, Maggie Yuen supports the scaling of production for the Neuron and Penumbra System brands. The Chief Financial Officer collaborates with executive leadership to evaluate investment opportunities in new revascularization technologies. Through precise financial planning and risk management, the executive provides the stability required for sustained innovation, ensuring that the company achieves its long-term growth objectives while navigating the complexities of the international medical device landscape.
James Pray - President, International
James Pray, the President, International at Penumbra, directs the commercial operations and market expansion strategies outside the United States. Overseeing the distribution and marketing of neurovascular access systems and thrombectomy devices in Europe, Canada, Australia, and Japan, the President, International ensures that the company effectively penetrates diverse healthcare systems. This leadership role involves building strong relationships with regional distributors and healthcare providers to increase the adoption of the Neuron and Velocity brands. By tailoring commercial approaches to specific regional regulatory and clinical environments, James Pray drives consistent revenue growth across global territories. The President, International coordinates with the executive team to align international sales targets with global manufacturing capabilities. Through strategic market development and operational oversight, the executive expands the reach of the company's life-saving technologies, ensuring that patients in international markets gain access to the latest advancements in vascular care.
James Benenati - Chief Medical Officer
James Benenati, the Chief Medical Officer at Penumbra, directs the clinical strategy and medical research initiatives for the company. Overseeing the validation of neurovascular therapies and aspiration-based thrombectomy systems, the Chief Medical Officer ensures that all products meet the highest standards of clinical efficacy and patient safety. This leadership role involves engaging with medical professionals globally to gather insights that inform the design of next-generation revascularization devices. By bridging the gap between engineering teams and clinical practice, James Benenati accelerates the adoption of advanced medical technologies in hospitals worldwide. The Chief Medical Officer monitors clinical trial outcomes and regulatory requirements to ensure compliance across diverse international markets. Through rigorous medical oversight, the executive validates the performance of the 3D brand and other core product lines, ultimately enhancing the standard of care for patients suffering from complex vascular conditions.
Explore Leadership Teams in Manufacturing
Biomerics designs, develops, and produces medical devices for diagnostic and interventional procedures. Their services include engineering, advanced components, and full contract manufacturing. Their headquarters is in Salt Lake City, Utah.
Company Leadership AM
FD
CM
ResMed is a global healthcare technology company that develops innovative medical devices, digital health solutions, and cloud-connected software to improve the diagnosis, treatment, and management of sleep disorders, respiratory conditions, and care delivered outside traditional hospital settings. The company partners with healthcare providers, patients, and caregivers to enhance health outcomes, streamline care delivery, and improve quality of life through connected technologies, data-driven insights, and ongoing innovation in medical care.
Company Leadership
AP
NM
Accuray develops and manufactures advanced radiation oncology systems designed to deliver precise cancer treatment solutions. The company specializes in creating innovative medical devices that enable clinicians to target tumors with exceptional accuracy while minimizing exposure to surrounding healthy tissue. This focus on precision has shaped the organization's technical approach and product development strategy across its portfolio. The company's radiation oncology systems integrate sophisticated imaging, planning, and delivery technologies to support comprehensive cancer care. By combining real-time imaging capabilities with adaptive treatment planning, Accuray's platforms allow medical teams to adjust therapy in response to anatomical changes during treatment courses. This technological integration addresses a critical challenge in oncology: maintaining treatment efficacy while reducing potential side effects that can impact patient quality of life. Accuray serves hospitals, cancer treatment centers, and specialized radiation oncology facilities globally. The company's systems support treatment of various cancer types across different anatomical sites, from brain and head-and-neck tumors to thoracic and abdominal malignancies. Healthcare providers rely on Accuray's technology to expand their treatment capabilities and improve clinical outcomes for patients who might otherwise have limited options.
Company Leadership MR
Headquartered in Glen Allen, Virginia, Owens & Minor is a distributor of national name-brand medical and surgical supplies and a healthcare supply-chain management company. With a diverse product and service offering and distribution centers throughout the United States. The company serves hospitals, integrated healthcare systems, alternate care locations, group purchasing organizations, and the federal government. Owens & Minor provides technology and consulting programs that improve inventory management and streamline logistics across the entire medical supply chain--from origin of product to patient bedside.
Company Leadership
JH
FC
DM
Frequently Asked Questions Regarding Penumbra Top Executives and Leadership Team
Unlock more people and company data
